Rznomics Inc. shared its platform technology and program development progress

Rznomics revealed its platform technology and program development progress

Seongwoo Hong, vice president & head of development department made a presentation on '2022 LOG IN IR EXPO 100' held at the FKI Hall in Yeouido.

Rznomics develops RNA-targeting drugs using an RNA replacement enzyme platform.

Rznomics' platform uses a ribozyme that causes trans-splicing and a therapeutic transgene that encodes a therapeutic effect inducer.

It is a method in which DNA linked to a ribozyme and a therapeutic gene is delivered into the cell using a vector such as adenovirus, and drug RNA transcribed from the cell targets the target RNA.

A ribozyme specifically binds to a target RNA and then replaces a portion of the target RNA with a therapeutic gene RNA by trans-splicing method. The function of the target disease RNA is lost and the protein encoded by the therapeutic gene is expressed.

Global drug development based on trans-splicing is still in its infancy, and Ascidian Therapeutics, which develops RNA-targeted therapeutics using trans-splicing, announced its $50 million Series A funding last month.